Roche Holding AG (ROG.VX)

ROG.VX on Virt-X Level 1

228.00CHF
31 Jul 2013
Price Change (% chg)

CHF-3.50 (-1.51%)
Prev Close
CHF231.50
Open
CHF230.00
Day's High
CHF230.00
Day's Low
CHF226.30
Volume
1,426,570
Avg. Vol
1,420,271
52-wk High
CHF258.60
52-wk Low
CHF170.00

ROG.VX

Chart for ROG.VX

About

Roche Holding AG is a Swiss pharmaceuticals and diagnostics holding company. It belongs to the Roche Group that operates through subsidiaries and associated companies around the world. It discovers, develops and provides diagnostic and therapeutic products and services from early detection and prevention of diseases to... (more)

Overall

Beta: 0.90
Market Cap (Mil.): CHF196,888.30
Shares Outstanding (Mil.): 862.56
Dividend: 7.35
Yield (%): 3.22

Financials

  ROG.VX Industry Sector
P/E (TTM): 20.44 37.93 37.76
EPS (TTM): 11.15 -- --
ROI: 22.90 19.48 18.76
ROE: 71.75 20.17 19.59
Search Stocks

Alexion shares rise after report of approach by Roche

- Shares of Alexion Pharmaceuticals Inc rose more than 7 percent on Tuesday following a report that Swiss drugmaker Roche Holding AG made an informal approach to the biotech company last week about a takeover.

30 Jul 2013

Alexion shares rise after report of approach by Roche

July 30 - Shares of Alexion Pharmaceuticals Inc rose more than 7 percent on Tuesday following a report that Swiss drugmaker Roche Holding AG made an informal approach to the biotech company last week about a takeover.

30 Jul 2013

Roche tops forecast as new cancer drugs gain momentum

BASEL, Switzerland - Swiss pharmaceuticals firm Roche beat first-half profit forecasts as strong sales of its mainstay cancer drugs and some new treatments supported its view that it can withstand competition from cheap, copycat drugmakers.

25 Jul 2013

UPDATE 3-Roche tops forecast as new cancer drugs gain momentum

* Shares rise 1.0 pct (Adds CEO comments of cardio metabolic research, M&A, updates shares)

25 Jul 2013

Roche tops forecast as new cancer drugs gain momentum

BASEL, Switzerland - Swiss pharmaceuticals firm Roche beat first-half profit forecasts as strong sales of its mainstay cancer drugs and some new treatments supported its view that it can withstand competition from cheap, copycat drugmakers.

25 Jul 2013

Top three drugs boost Roche's first-half earnings

BASEL, Switzerland, July 25 - Strong sales of its top three drugs and new expensive breast cancer treatments helped Roche Holding AG post a bigger-than-expected rise in first-half core earnings of 10 percent.

25 Jul 2013

Roche takes its hunt for a new chairman further afield

ZURICH, July 22 - Swiss drugmaker Roche faces the prospect of hiring an outsider to replace its chairman of 16 years after its most suitable board members turned down the job.

22 Jul 2013

UPDATE 1-Alexion valuation could choke any Roche bid

* Roche seeking financing for potential Alexion bid- sources

15 Jul 2013

Alexion valuation could choke any Roche bid

* Roche seeking financing for potential Alexion bid- sources

14 Jul 2013

Roche seeks financing for potential Alexion bid: sources

NEW YORK/LOS ANGELES - Swiss drugmaker Roche Holding AG is seeking financing for a potential bid for Alexion Pharmaceuticals Inc , a transaction that if successful would be the largest healthcare deal of the year, two people familiar with the matter said on Friday.

12 Jul 2013

Earnings vs. Estimates

Search Stocks